Nkarta (NKTX)

Natural killer cells are part of the innate immune system and can identify and destroy abnormal cells without the same antigen-specific priming required by some other immune cells. Nkarta combines NK-cell expansion methods with genetic engineering to improve targeting, potency, and persistence in the body. This approach is intended to capture some of the benefits associated with cell therapy while potentially offering faster availability, more scalable manufacturing, and broader patient access than personalised autologous products.

The company’s programmes include engineered NK cell candidates directed at targets involved in cancer and immune-mediated disease. NKX019, for example, is designed to target CD19, a marker found on B cells, and has been explored in settings including B-cell malignancies and autoimmune diseases where pathogenic B cells may play a role. Nkarta has also worked on NK-cell approaches aimed at tumour-associated stress ligands in difficult-to-treat cancers.

Nkarta remains a development-stage company, so its prospects depend on clinical evidence, manufacturing execution, regulatory review, and financing capacity. Its distinction lies in applying cell engineering to NK biology, an area that could complement or compete with CAR-T and other advanced immune cell therapies if safety, efficacy, and scalability are demonstrated.